688363-48-6

Basic information

• Product Name: 8-Bromo-4Hbenzo[1,4]oxazin-3-one
• Synonyms: 8-Bromo-4Hbenzo[1,4]oxazin-3-one;8-bromo-2H-benzo[b][1,4]oxazin-3(4H)-one
• CAS NO: 688363-48-6
• Molecular Formula: C₈H₆BrNO₂
• Molecular Weight: 228.04
• Mol File: 688363-48-6.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 8-Bromo-4Hbenzo[1,4]oxazin-3-one(CAS DataBase Reference)
• NIST Chemistry Reference: 8-Bromo-4Hbenzo[1,4]oxazin-3-one(688363-48-6)
• EPA Substance Registry System: 8-Bromo-4Hbenzo[1,4]oxazin-3-one(688363-48-6)

Safety Data

• Hazardous Substances Data: 688363-48-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
8-Bromo-4Hbenzo[1,4]oxazin-3-one is used as a pharmaceutical candidate for its potential activity in various biological assays, making it a promising compound for drug discovery and development.
Used in Materials Science:
8-Bromo-4Hbenzo[1,4]oxazin-3-one is used in the development of new materials due to its unique structure and properties, which may offer novel applications in materials science.

Upstream product

• 28165-50-6 2-amino-6-bromophenol 
• 79-04-9 chloroacetyl chloride 

Downstream Products

• 625394-65-2 8-bromo-3,4-dihydro-2H-benzo[1,4]oxazine 

Relevant articles and documents

HETEROCYCLE CDK INHIBITORS AND THEIR USE THEREOF

The disclosure is directed to, in part, to heterocycle CDK inhibitors, pharmaceutical compositions comprising the same, as well as methods of their use and preparation.

PIKFYVE KINASE INHIBITORS

The present invention relates to compounds useful as inhibitors of phosphatidylinositol-3-phosphate 5-kinase (PIKfyve) as well as their use for treating diseases and disorders associated with PIKfyve.

Development of small-molecule Trypanosoma brucei N-myristoyltransferase inhibitors: Discovery and optimisation of a novel binding mode

The enzyme N-myristoyltransferase (NMT) from Trypanosoma brucei has been validated both chemically and biologically as a potential drug target for human African trypanosomiasis. We previously reported the development of some very potent compounds based around a pyrazole sulfonamide series, derived from a high-throughput screen. Herein we describe work around thiazolidinone and benzomorpholine scaffolds that were also identified in the screen. An X-ray crystal structure of the thiazolidinone hit in Leishmania major NMT showed the compound bound in the previously reported active site, utilising a novel binding mode. This provides potential for further optimisation. The benzomorpholinone was also found to bind in a similar region. Using an X-ray crystallography/structure-based design approach, the benzomorpholinone series was further optimised, increasing activity against T. brucei NMT by >1000-fold. A series of trypanocidal compounds were identified with suitable in vitro DMPK properties, including CNS exposure for further development. Further work is required to increase selectivity over the human NMT isoform and activity against T. brucei. HATs off to diversity! Screening a diverse library against Trypanosoma brucei N-myristoyltransferase (NMT) identified hits based on thiazolidinone and benzomorpholine scaffolds. X-ray crystallography of these compounds bound to Leishmania major NMT revealed novel active site binding conformations. Using the structural information, the benzomorpholine scaffold was optimised to a blood-brain barrier penetrant compound with activity against TbNMT of 0.002 μm.

PHARMACEUTICAL COMPOSITION FOR TREATING DIABETES

Provided is a compound represented by the following general formula (I), or a pharmaceutically acceptable salt thereof. This novel compound has a glycogen-synthase activation ability, but activates a receptor PPAR to a low degree and is highly safe. In th

NOVEL BICYCLIC NITROGEN CONTAINING HETEROARYL TGR5 RECEPTOR MODULATORS

Novel compounds of Formula I:or an enantiomer, diastereomer, tautomer, prodrug or salt thereof, wherein m, Q, T, U, V, ring A, X, Y, R3, R4, R4a, R5a, R5b, R5c, R5d, R5e, R6a, R6b, and R6c are defined herein, are provided which are TGR5 G protein-coupled receptor modulators. TGR5 G protein-coupled receptor modulators are useful in treating, preventing, or slowing the progression of diseases requiring TGR5 G protein-coupled receptor modulator therapy. Thus, the disclosure also concerns compositions comprising these novel compounds and methods of treating diseases or conditions related to the activity of the TGR5 G protein-coupled receptor by using any of these novel compounds or a composition comprising any of such novel compounds.

Synthesis and discovery of 2,3-dihydro-3,8-diphenylbenzo[1,4]oxazines as a novel class of potent cholesteryl ester transfer protein inhibitors

2,3-Dihydro-3,8-diphenylbenzo[1,4]oxazines were identified as a new class of potent cholesteryl ester transfer protein inhibitors. The most potent compound 6a (IC50 = 26 nM) possessed a favorable pharmacokinetic profile with good oral bioavailability in rat (F = 53%) and long human liver microsome stability (t1/2 = 62 min). It increased HDL-C in human CETP transgenic mice and high-fat fed hamsters. The structure and activity relationship of this series will be described in this Letter.

3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE AND THIAZINE DERIVATIVES AS CETP INHIBITORS

The invention is directed to compounds of Formula (I) described herein useful as CETP inhibitors, compositions containing them, and methods of using them.

Substituted benzoxazinones and uses thereof

The invention provides compound of the Formula: and pharmaceutically acceptable salts or prodrugs thereof, wherein Y, Z, R1, R2, R3, R4, R5, R6, R7, R8, R9,